Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Cognition Therapeutics Inc CGTX

Healthcare
Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of small molecule therapeutics targeting age-related degenerative disorders of the central nervous system and retina. The Company is investigating its lead candidate CT1812 in clinical programs in Alzheimer's disease, dementia with Lewy bodies and dry age-related macular... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:CGTX)

Cognition Therapeutics Reports Financial Results for the Third Quarter 2024 and Provides Business and Clinical Update

GlobeNewswire 11 days ago

Cognition Therapeutics to Present at Zacks SCR Life Sciences Investor Forum

GlobeNewswire 12 days ago

Cognition Therapeutics Presents Poster of Participant Demographics from Phase 2 Dementia with Lewy Bodies Study at CTAD

GlobeNewswire October 31, 2024

Cognition Therapeutics Announces Results of Pre-specified Analysis of SHINE Study Data Presented at CTAD

GlobeNewswire October 29, 2024

Analyses from Cognition's Positive Phase 2 'SHINE' Study of CT1812 in Mild-to-Moderate Alzheimer's Disease will be Presented in a Podium Presentation at CTAD

GlobeNewswire October 23, 2024

Cognition Therapeutics Releases New Episode of "Conversations" Podcast: Executing Clinical Research in Dementia with Lewy Bodies (DLB)

GlobeNewswire October 22, 2024

Cognition Therapeutics Will Participate in the Roth Healthcare Opportunities Conference

GlobeNewswire October 2, 2024

Cognition Therapeutics Supports Lewy Body Dementia Awareness Month and the Need for Improved Treatments for the Second Most Common Dementia

GlobeNewswire October 1, 2024

Cognition Therapeutics to Participate in Upcoming September 2024 Investor Conferences

GlobeNewswire September 3, 2024
View More News ››

Opinion & Analysis (NDAQ:CGTX)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:CGTX)

Life Sciences Investor Forum Agenda Announced for November 1

Breaking News: $CGTX Life Sciences Investor Forum Agenda Announced for November 14thNEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Virtual...
whytestocks - 12 days ago

Cognition Therapeutics Publishes EEG Findings from Phase 2 S

Breaking News: $CGTX Cognition Therapeutics Publishes EEG Findings from Phase 2 SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer'...
whytestocks - August 22, 2024

Cognition Therapeutics to Host Investor Webcast to Discuss R

Just In: $CGTX Cognition Therapeutics to Host Investor Webcast to Discuss Results from Proof-of-Concept Phase 2 SHINE Study of CT1812 in...
whytestocks - July 26, 2024

Ok, I will start, stock closed at $2.17 5-19-23-could be ..

interesting. Different take on AD. High risk play but I could make a case for this to be a $50-$100 stock in 24 months if they can prove...
ubiquitousman - May 20, 2023
View more Bullboard ››

Indiva Ltd

Indiva Ltd

Indiva Limited, through its indirect wholly owned subsidiary, Indiva Inc., is a Canada-based producer of cannabis servicing ...
View More »